Results 61 to 70 of about 1,518 (207)

Updated Review on Treatment of Atopic Dermatitis [PDF]

, 2023
La dermatitis atópica (DA) es una dermatosis inflamatoria crónica o crónicamente recurrente, asociada a múltiples desencadenantes y con un mecanismo fisiopatológico complejo. Se caracteriza por una expresión clínica, signos y síntomas heterogéneos.
Armario Hita, José Carlos, Carrascosa, J. M., Dodero-Anillo, J. M., Galán-Gutiérrez, M., Ruiz-Villaverde, R.   +4 more
core   +1 more source

Spectrophotometric Study of Charge-Transfer Complexes of Ruxolitinib with Chloranilic Acid and 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone: An Application to the Development of a Green and High-Throughput Microwell Method for Quantification of Ruxolitinib in Its Pharmaceutical Formulations

Molecules, 2023
Ruxolitinib (RUX) is a potent drug that has been approved by the Food and Drug Administration for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
Khalid A. Aljaber, Ibrahim A. Darwish, Abdullah M. Al-Hossaini   +2 more
doaj   +1 more source

Emerging drugs for the treatment of vitiligo [PDF]

, 2020
Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin. There has been a great advance in understanding the pathological basis, which has led to the development and utilization of various new molecules in treating ...
Goldust, M., Grabbe, S., Karagaiah, P., Lotti, T., Parsad, D., Schwartz, R. A., Sigova, J., Valle, Y., Vojvodic, P., Zerbinati, N.   +9 more
core   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

Treatment of cutaneous Langerhans cell histiocytosis with ruxolitinib 1.5% cream

JAAD Case Reports
Jeffrey Sobieraj, Jana Hatahet, Tyler D. Menge, Wasim Nasir   +3 more
openalex   +3 more sources

Pediatric Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T‐cell lymphoma (PCAECTCL) is a rare and aggressive malignancy, with limited documented cases in pediatric patients. This report presents a unique case of a 9‐year‐old female with PCAECTCL, characterized by widespread erythematous annular lesions that exhibited an indolent clinical ...
Carrie Meng, Auris Huen, David McCall, Phyu P. Aung, Priyadharsini Nagarajan, Valentina Nardi, Carlos A. Torres‐Cabala   +6 more
wiley   +1 more source

S1‐Guideline for diagnosis and therapy of necrobiosis lipoidica

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Necrobiosis lipoidica (NL) is a rare granulomatous skin disease of unknown etiology that occurs frequently in association with diabetes mellitus and other comorbidities. The predilection site is the lower leg, particularly the pretibial areas. The exact pathogenesis remains unclear.
Cornelia Erfurt‐Berge, Regina Renner, Melanie Peckruhn, Jörg Tittelbach, Dorothea Terhorst‐Molawi, Friederike Kauer, Joachim Dissemond   +6 more
wiley   +1 more source

The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report

JAAD Case Reports
Deesha Desai, BS, Ambika Nohria, BA, Kristen Lo Sicco, MD, Jerry Shapiro, MD   +3 more
doaj   +2 more sources

27630 Assessing signs and symptoms of hidradenitis suppurativa from the patient perspective [PDF]

, 2021
Background: Qualitative research was conducted to develop a patient reported outcome (PRO) measure assessing symptoms/signs of hidradenitis suppurativa (HS), the HS Symptom Diary (HSSD).
Alavi, aFSANEH, Baradaran, Sarah, Colwell, Hilary H, Hamzavi, Iltefat H, Han, Chenglong, Mathias, Susan D, Song, Michael   +6 more
core   +1 more source

Therapeutic advances in pruritus as a model of personalized medicine

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung, Ramsey Kubofcik, Brian S. Kim   +2 more
wiley   +1 more source